De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
Table 3
Characteristics of 78 de novo donor specific HLA antibodies (dnDSAs) detected in 39 DSA positive kidney recipients.
Variables
Total number of dnDSAs ()
dnDSAs occurring within year 1 ()
dnDSAs occurring beyond year 1 ()
value
HLA class I dnDSAs
40 (51%)
11 (42%)
29 (56%)
0.34
HLA class II dnDSAs
38 (49%)
15 (58%)
23 (44%)
0.34
HLA class I dnDSAs,
4678 ± 4516
4838 ± 4717
4618 ±4521
0.89
HLA class II dnDSAs,
12033 ± 8410
10629 ± 7568
12949 ±8960
0.41
HLA-A
18 (23%)
5 (19%)
13 (25%)
0.78
HLA-B
15 (19%)
3 (11%)
12 (23%)
0.36
HLA-C dnDSAs
7 (9%)
3 (11%)
4 (7%)
0.68
HLA-DR
7 (9%)
4 (15%)
3 (6%)
0.21
HLA-DQ
30 (38%)
11 (42%)
19 (36%)
0.63
HLA-DP dnDSAs
1 (1%)
0
1 (2%)
1.00
C1q binding of dnDSAs
44 (56%)
17 (65%)
27 (52%)
0.33
HLA class I dnDSAs
20 (26%)
7 (27%)
13 (25%)
1.00
HLA class II dnDSAs
24 (31%)
10 (38%)
14 (27%)
0.31
C3d binding of dnDSAs
18 (23%)
7 (27%)
11 (21%)
0.58
HLA class I dnDSAs
1 (1%)
1 (4%)
0
0.33
HLA class II dnDSAs
17 (22%)
6 (23%)
11 (21%)
1.00
Percentages are calculated on the total number of antibodies from each group indicated at the top of the respective columns. All data are reported as absolute numbers, unless otherwise specified. Data reported as mean ± sd. The number of antibodies detailed in this table is higher than that reported in Table 2, as some patients have multiple DSAs at this locus. MFI: mean fluorescence intensity.
